Company Overview of Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases. The company offers disease-modifying therapeutics for cystic fibrosis; and also develops treatments for diseases caused by an imbalance in the proteostasis network and characterized by defects in protein folding, trafficking, and clearance, including genetic, neurodegenerative, and retinal degenerative diseases. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics,...
200 Technology Square
Cambridge, MA 02139
Founded in 2006
Key Executives for Proteostasis Therapeutics, Inc.
Chief Executive Officer, President and Director
Interim Chief Financial Officer
Chief Medical Officer and Executive Vice President
Senior Vice President of Drug Discovery
Principal Accounting Officer
Compensation as of Fiscal Year 2015.
Proteostasis Therapeutics, Inc. Key Developments
Proteostasis Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Dec 23 15
Proteostasis Therapeutics, Inc. filed its Annual on Dec 23, 2015 for the period ending Dec 31, 2014. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Proteostasis Therapeutics Incorporated Names Ben Munoz as Senior Vice President, Drug Discovery
Dec 14 15
Proteostasis Therapeutics Incorporated has named Ben Munoz, PhD, as its senior vice president, Drug Discovery. Dr. Munoz will be responsible for all of the company's drug discovery research activities and operations. He will also be responsible for expanding the pipeline with new drug candidates by managing activities related to hit identification, lead optimisation, drug candidate selection and all related aspects of chemistry, manufacturing and controls. Dr. Munoz joined Proteostasis in 2013.
Proteostasis Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 11:55 AM
Sep 25 15
Proteostasis Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 11:55 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Markus Haeberlein, Chief Scientific Officer and Senior Vice President.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 1, 2015